Tuesday, 21 April 2015
C H Spurgeon’s Morning Devotional for 21st March
"I know that my Redeemer liveth."
The marrow of Job's comfort lies in that little word "My"-"My Redeemer," and in the fact that the Redeemer lives. Oh! to get hold of a living Christ. We must get a property in Him before we can enjoy Him. What is gold in the mine to me? Men are beggars in Peru, and beg their bread in California. It is gold in my purse which will satisfy my necessities, by purchasing the bread I need. So a Redeemer who does not redeem me, an avenger who will never stand up for my blood, of what avail were such? Rest not content until by faith you can say "Yes, I cast myself upon my living Lord; and He is mine." It may be you hold Him with a feeble hand; you half think it presumption to say, "He lives as my Redeemer;" yet, remember if you have but faith as a grain of mustard seed, that little faith entitles you to say it. But there is also another word here, expressive of Job's strong confidence, "I know." To say, "I hope so, I trust so" is comfortable; and there are thousands in the fold of Jesus who hardly ever get much further. But to reach the essence of consolation you must say, "I know." Ifs, buts, and perhapses, are sure murderers of peace and comfort. Doubts are dreary things in times of sorrow. Like wasps they sting the soul! If I have any suspicion that Christ is not mine, then there is vinegar mingled with the gall of death; but if I know that Jesus lives for me, then darkness is not dark: even the night is light about me. Surely if Job, in those ages before the coming and advent of Christ, could say, "I know," we should not speak less positively. God forbid that our positiveness should be presumption. Let us see that our evidences are right, lest we build upon an ungrounded hope; and then let us not be satisfied with the mere foundation, for it is from the upper rooms that we get the widest prospect. A living Redeemer, truly mine, is joy unspeakable.
Thursday, 16 April 2015
Thursday, April 16, 2015
The MMR vaccine is back in the news. Australian parents will lose their welfare benefits if they don’t vaccinate their children, while up to 86 per cent of children who caught measles during the ‘Disneyland outbreak’ in California last December were vaccinated, a new study has revealed.
Australian Prime Minister Tony Abbott has announced that parents who refuse to vaccinate their children will lose up to $11,000 of welfare benefits. Parents can opt out of vaccinations on medical or religious grounds, or because they are “conscientious objectors”.
But, from January next year, the conscientious objection opt-out will be removed in Abbott’s new “no jab, no pay” policy. Religious exemptions will also be tightened, and will apply only to religious bodies “approved by the government”.
The Australian government reckons that 39,000 families could lose their rights to welfare benefits.
US health authorities are also looking to tighten up on exemptions after the measles outbreak last December, in which around 140 children were infected. It is thought to have started at Disneyland in California.
But a new study reckons that up to 86 per cent of the infected children had received all their MMR jabs. “Given the highly contagious nature of measles, vaccination rates of 96 per cent to 99 per cent are necessary to preserve herd immunity and prevent future outbreaks,” say the researchers from Massachusetts Institute of Technology
(Sources: CCN, April 13, 2015; JAMA Pediatrics, published online, March 16, 2015)
Thursday, 9 April 2015
Mitochondrial dysfunction and the role of cytokines in ME/CFS: Preliminary results from research being funded by The MEA Ramsay Research Fund and the Medical Research Council | 2 April 2015
From The FASEBJournal, published by the Federation of American Societies for Experimental Biology, April 2015.
The Role of Cytokines in Muscle Fatigue in Patients with Chronic Fatigue Syndrome (CFS).
Kate Earl(1), Giorgos Sakellariou(1), Daniel Owens(2), Melanie Sinclair(1), Manuel Fenech(1), Graeme Close(2), Clare Lawton(3), Louise Dye(3), Micheal Beadsworth(1) and Anne McArdle(1)
1) Institute of Ageing and Chronic Disease University of Liverpool United Kingdom
2) RISES Liverpool John Moores University United Kingdom
3) Psychological Sciences University of Leeds United Kingdom
CFS is characterized by profound levels of persistent/recurrent fatigue. It is proposed that chronic, low level inflammation may play a role in this fatigue.
We recruited 100 untreated patients with CFS (average age 33±12) and 100 age and sex matched healthy controls (HCs).
Serum levels of TNF-α were assessed using ELISA. Subjective fatigue was determined by questionnaire and muscle function tests were undertaken in subgroups in which maximal voluntary contraction (MVC), electrically stimulated muscle force generation and rate of fatigue were assessed in the quadriceps muscle.
Subjective fatigue was higher in patients with CFS compared with HCs. Preliminary analyses showed that serum TNF-α was undetectable in 97% of HCs, whereas 15% of patients with CFS had detectable (4.4+/-0.18pg/ml) serum TNF-α. MVC was significantly reduced in subjects with CFS compared with HCs.
No difference was seen in stimulated muscle fatigue between groups.
This preliminary data suggests that a sub-group of patients with CFS may have low level inflammation and analyses are underway to further characterise other inflammatory markers in serum and muscle of these patients and to determine whether such changes could affect indices of muscle function or central fatigue.
Funded by MRC, BBSRC and the ME Association.
Saturday, 4 April 2015
From the Bible -
John 3 v 16 –
For God so loved the world, that He gave His only begotten Son, that whosoever believeth in Him should not perish, but have everlasting life.
1 Corinthians 15 v 1-4 –
Moreover, brethren, I declare unto you the gospel which I preached unto you, which also ye have received, and wherein ye stand; By which also ye are saved, if ye keep in memory what I preached unto you, unless ye have believed in vain. For I delivered unto you first of all that which I also received, how that Christ died for our sins according to the scriptures; And that He was buried, and that He rose again the third day according to the scriptures.
1 Peter 2 v 21-24 –
For even hereunto were ye called: because Christ also suffered for us, leaving us an example, that ye should follow His steps: Who did no sin, neither was guile found in His mouth: Who, when He was reviled, reviled not again; when He suffered, He threatened not; but committed Himself to Him that judgeth righteously: Who His own self bare our sins in His own body on the tree, that we, being dead to sins, should live unto righteousness: by Whose stripes ye were healed.
O praise the risen Prince of Light,
Who, clothed in human clay,
Entered into the gates of death,
And tore those bars away!
Death is no more the king of fear
Since our Emmanuel rose;
He took the tyrant’s sting away,
And banished all its woes.
See how the Conqueror mounts aloft,
And to His Father flies,
With scars of honour in His flesh,
And triumph in His eyes.
There our exalted Saviour reigns,
And pours His blessings down;
His triumph well rewards His pains,
And bids Him wear the crown.
Angels and saints in wonder join,
Their sweetest voices raise;
Let Heaven above and earth below
Sound our Emmanuel’s praise.
Isaac Watts, 1674-1748
Wednesday, 1 April 2015
Welcome to London for the IIMEC10 International ME Conference for 2015.
Invest in ME is a UK charity facilitating and funding a strategy of biomedical research into Myalgic Encephalomyelitis (ME or ME/CFS) and promoting better education about ME.
IIMEC10 is the tenth annual CPD-accredited biomedical research conference organised and hosted by the charity and now attracts presenters, researchers, physicians, patient groups and journalists from around the world.
Below one will find a description of the conference, how to register, the venue and details of the presenters.
Research into Myalgic Encephalomyelitis - specifically biomedical research into ME - has, thanks to conferences and research meetings organised by Invest in ME, emerged into the mainstream of research and is receiving increasingly more attention from both major research institutes in several countries as well as national health organisations.
Organisations responsible for medical research in several countries have already stated that ME would receive more urgent attention. In Norway the Norwegian Health Directorate have allocated funding for biomedical research into ME following the 2011 double blind randomised clinical trial using Rituximab (Anti-CD20 monoclonal antibody) by Fluge et al (PLoS 6:10.Oct 2011) to successfully treat ME patients. There is increasing research evidence of immune dysfunction in ME patients.
The UK MRC has previously stated - "There is now preliminary evidence supporting the view that inflammatory mechanisms in the brain and spinal cord may underlie the pathophysiology of some severe disease CFS/ME phenotypes." The IIMEC10 conference will show some of the major initiatives being taken to set up a collaborative strategy for biomedical research into ME to further this complex but exciting area of research leading to appropriate patient care and mainstreaming this field of research as well as this disease.
WHO SHOULD ATTEND
The conference will appeal to healthcare professionals, doctors, nurses, paediatricians, occupational therapists, researchers, ME support groups, people with ME and those working in social services, educational support and the media. The conference provides an opportunity for people within government, health departments, social services and education to be able to be informed of the true nature of ME and of the current status of diagnosis, treatment and current/future biomedical research possibilities.
If help is needed regarding any aspect of the conference please use our Contact Us page. On the conference day the charity will have a number of helpers to assist from the point of registration through to the end of the day. Our main web site is at www.investinme.org
PAST IiME CONFERENCES
IIMEC10 will be our tenth annual international conference for ME. The conference regularly attracts clinicians, researchers, healthcare staff, charities, support groups and patients and carers from twenty countries around the world.This allows unique networking opportunities and increase the potential for one of the charity's main objectives - international collaboration between researchers.